Journal of Medical Economics

Title Publication Date Language Citations
Quantifying preferences for urea cycle disorder treatments using a discrete choice experiment2024/03/31English
The economic burden of systemic lupus erythematosus in United Arab Emirates2024/03/06English
Clinical and economic burden of systemic lupus erythematosus in Colombia2024/03/06English
Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden2024/03/26English
The economic burden of systemic lupus erythematosus in Taiwan2024/03/06English
Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study2024/04/10English
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma2024/04/01English
Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors2023/04/17English
Incidence and medical costs of chronic obstructive respiratory disease in Spanish hospitals: a retrospective database analysis2023/02/27English
Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type2024/02/13English
Challenges in health economics research: insights from real-world examples2024/02/06English
Benefits of MR-proADM-guided decision-making in the emergency department: clinical and economic evaluation in Italy, Germany, Spain, and the UK2023/06/30English
Preferences and values for government policies on infectious disease outbreaks and epidemics for the Japanese population: a conjoint analysis2023/06/20English
Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib2023/07/17English
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan2023/08/12English
Budget impact analysis of a bovine pericardial aortic bioprosthesis versus mechanical aortic valve replacement in adult patients with aortic stenosis in Romania2023/08/08English
Immunization, not vaccination: monoclonal antibodies for infant RSV prevention and the US vaccines for children program2023/08/04English
Clinical and economic outcomes of assigning percutaneous coronary intervention patients to contrast-sparing strategies based on the predicted risk of contrast-induced acute kidney injury2024/04/22English
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland2024/04/23English
Value-based payment and financing for cell and gene therapies: challenges and potential solutions2024/04/27English
Economic and healthcare resource utilization assessments of pet imaging in coronary artery disease diagnosis: a systematic review and discussion of opportunities for future economic evaluations2024/04/23English
Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data2024/04/19English
The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs2024/04/19English
Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis2024/04/27English
A matching-adjusted indirect comparison of results from REDUCE and RESPECT—two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke2024/02/29English
Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study2024/03/11English
Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study2023/09/13English
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden2023/09/15English
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective2023/09/09English
Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis2023/08/26English